Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2831781 in active ulcerative colitis (Phase 2, double-blind, placebo-controlled)
2018-003278-28Phase 2Unknown
- Sponsor
- GSK
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GSK2831781 with Placebo (2 arms). Primary endpoint: Incidence of adverse events and serious adverse events during the Double-Blind Induction Phase. Status: unknown.
02
Drugs
IMP731
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-003278-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003278-28.